文献速递呼吸危重症与机械通气

五十年ARDS研究:急性呼吸窘迫综合征的细胞治疗——生物学与潜在治疗价值

Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01

基于多项临床前研究,细胞治疗已成为急性呼吸窘迫综合征(ARDS)的潜在新疗法。骨髓、脂肪和脐带来源的间充质干细胞/基质细胞(MSCs)具有最多的实验数据支持其对感染性和非感染性肺损伤的潜在疗效。MSCs通过释放旁分泌因子、微囊泡和转移线粒体发挥抗炎和促消退作用,并上调钠依赖性肺泡液体清除以增强肺水肿消退,同时具有抗菌效应。2a期临床试验正在进行,两项1期试验未报告严重不良事件,但大规模生产、细胞效力检测及高炎症内型患者选择等问题仍需进一步研究。

要点

  • 骨髓、脂肪和脐带来源的MSCs对感染性和非感染性肺损伤具有潜在疗效。
  • MSCs通过旁分泌因子、微囊泡、线粒体转移及上调肺泡液体清除发挥抗炎促消退作用。
  • MSCs还具有抗菌效应,2a期临床试验正在进行,两项1期试验未报告严重不良事件。

核心结论

  • 细胞治疗,特别是MSCs,是ARDS的潜在新疗法,但需进一步研究以解决规模化生产、效力检测和患者选择等问题。

研究设计与样本

  • 基于多项临床前研究的综述,总结MSCs治疗ARDS的生物学机制和潜在治疗价值,并提及正在进行的2a期临床试验和已完成的两项1期试验。

主要发现

  • MSCs通过释放旁分泌因子、微囊泡和转移线粒体,对损伤的肺内皮和肺泡上皮发挥抗炎和促消退作用。
  • MSCs通过上调钠依赖性肺泡液体清除增强肺水肿消退。
  • MSCs通过释放抗菌因子和上调单核/巨噬细胞吞噬作用发挥抗菌效应。
  • 两项1期试验未报告任何严重不良事件。

临床怎么用

  • 细胞治疗可能成为ARDS的新治疗选择,但需进一步确定大规模生产、冷冻保存细胞复苏、细胞效力检测等最佳方法。
  • 对于高炎症内型的ARDS患者,靶向使用MSCs可能进一步增强疗效。

局限性

  • 需进一步研究确定大规模生产的最佳方法、冷冻保存细胞复苏用于临床、定义细胞效力检测以及确定MSCs来源条件培养基的治疗潜力。
  • ARDS是异质性综合征,需针对高炎症内型患者进一步评估MSCs的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On the basis of several preclinical studies, cell-based therapy has emerged as a potential new therapeutic for acute respiratory distress syndrome (ARDS). Of the various cell-based therapy options, mesenchymal stem/stromal cells (MSCs) from bone marrow, adipose tissue, and umbilical cord have the most experimental data to support their potential efficacy for lung injury from both infectious and noninfectious causes. Mechanistically, MSCs exert their beneficial effects by release of paracrine factors, microvesicles, and transfer of mitochondria, all of which have antiinflammatory and pro-resolving effects on injured lung endothelium and alveolar epithelium, including enhancing the resolution of pulmonary edema by up-regulating sodium-dependent alveolar fluid clearance. MSCs also have antimicrobial effects mediated by release of antimicrobial factors and by up-regulating monocyte/macrophage phagocytosis. Phase 2a clinical trials to establish safety in ARDS are in progress, and two phase 1 trials did not report any serious adverse events. Several issues need further study, including: determining the optimal methods for large-scale production, reconstitution of cryopreserved cells for clinical use, defining cell potency assays, and determining the therapeutic potential of conditioned media derived from MSCs. Because ARDS is a heterogeneous syndrome, targeting MSCs to patients with ARDS with a more hyperinflammatory endotype may further enhance their potential for efficacy.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Laffey JG, Matthay MA. Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value. Am J Respir Crit Care Med. 2017. PMID: 28306336. doi:10.1164/rccm.201701-0107CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。